Strategies to enhance fibrinolysis
| Agents . | Target . | |
|---|---|---|
| TAFIa . | α2-Antiplasmin . | |
| Monoclonal antibodies | Bind to TAFI and block its activation (eg, MA-T9H11, MA-RT30D8, MA-TCK11A9, MA-TCK26D6, MA-T12D11, mAbTAFI/TM#16, MA-TCK27A4) | Bind to circulating and fibrin-bound α2-antiplasmin and neutralize its activity [eg, DS-9231 (TS-23)] |
| Small molecule inhibitors | Bind to TAFIa and block its activity (eg, DS-1040,* S62798) | Not reported |
| Agents . | Target . | |
|---|---|---|
| TAFIa . | α2-Antiplasmin . | |
| Monoclonal antibodies | Bind to TAFI and block its activation (eg, MA-T9H11, MA-RT30D8, MA-TCK11A9, MA-TCK26D6, MA-T12D11, mAbTAFI/TM#16, MA-TCK27A4) | Bind to circulating and fibrin-bound α2-antiplasmin and neutralize its activity [eg, DS-9231 (TS-23)] |
| Small molecule inhibitors | Bind to TAFIa and block its activity (eg, DS-1040,* S62798) | Not reported |
Under evaluation in phase 2 clinical trials; discussed in text.